| Identification | Back Directory | [Name]
2-Pyridineacetamide, N-[3-(6-amino-3-pyridazinyl)-2-propyn-1-yl]-N-(4-fluorophenyl)-3,5-bis(trifluoromethyl)- | [CAS]
2832047-80-8 | [Synonyms]
RP-6685
2-Pyridineacetamide, N-[3-(6-amino-3-pyridazinyl)-2-propyn-1-yl]-N-(4-fluorophenyl)-3,5-bis(trifluoromethyl)- | [Molecular Formula]
C22H14F7N5O | [MOL File]
2832047-80-8.mol | [Molecular Weight]
497.37 |
| Chemical Properties | Back Directory | [Boiling point ]
599.1±50.0 °C(Predicted) | [density ]
1.52±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 125 mg/mL (251.32 mM; Need ultrasonic) | [form ]
Solid | [pka]
4.36±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
RP-6685 is a potent, selective and orally active DNA polymerase theta (Polθ) inhibitor with an IC50 value of 5.8 nM (PicoGreen assay). RP-6685 shows antitumor efficacy in mouse tumor xenograft model[1]. RP-6685 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [in vivo]
RP-6685 (80 mg/kg; p.o.; BID for 21 days) exhibits potent antitumor efficacy in BRCA2-deficient HCT116 mice[1]. | Animal Model: | Female CD1 nude mice (HCT116 BRCA2+/+ and BRCA2-/- xenograft tumor models)[1] | | Dosage: | 80 mg/kg | | Administration: | p.o.; BID for 21 days | | Result: | Showed tumor regression during the first 8 days of treatment in BRCA2-/- HCT116 model, while did not inhibit tumor growth in BRCA2+/+ HCT116 tumors mice. |
| Animal Model: | CD1 mice (20-30 g)[1] | | Dosage: | 2.5 mg/kg | | Administration: | i.v. or p.o.; single dosage | | Result: | | CL (mL/min/kg) | Vdss (L/kg) | t1/2 (h) | F (%) | | 36.8 | 1.1 | 0.4 | 66 |
|
| [References]
[1] Bubenik M, et al. Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ. J Med Chem. 2022 Sep 20. DOI:10.1021/acs.jmedchem.2c00998 |
|
|